(Reuters) - The biotechnology company said the European Commission had approved its drug, which is already approved in the United States, for PNH, which destroys red blood cells.
Alexion, based in Cheshire, Connecticut, said it aimed to launch Soliris in one or more major European markets by the end of 2007.
Read more at Reuters.com Government Filings News
Alexion, based in Cheshire, Connecticut, said it aimed to launch Soliris in one or more major European markets by the end of 2007.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment